AstraZeneca launches Artery Explorer on second tour

Share this article:
AstraZeneca launches Artery Explorer on second tour
AstraZeneca launches Artery Explorer on second tour
AstraZeneca is redeploying its Artery Explorer for a second tour, using medical animation to help bring atherosclerosis to life.

The Artery Explorer, a truck-mounted, motion simulator-equipped fiberglass pod in which patients can view an animated voyage through a plaque-encrusted artery, will hit 16 US cities this year starting with a stop in Washington, DC, later this week. The company hosted a satellite media tour with Atlanta heart surgeon Dr. William Cooper of Emory University Hospital and WellStar Kennestone Hospital.

Sporting a new look, the Artery Explorer will be staying longer in the cities it visits—two weeks for most—and setting up at smaller venues like hospitals in addition to large events. Several cities have been added to the itinerary, including San Francisco, where it will appear at the Senior Games, and Las Vegas, at AARP's annual convention, as well as Cleveland, Indianapolis, Charleston, SC and Washington, DC. This year, visitors will also be asked to take an exit survey aimed at gauging their understanding of atherosclerosis and whether or not they will discuss it with friends, family and/or their physician.

PR agency of record for the tour is Edelman New York. The animation was created by London shop Radical Departures, and the pod is operated by Pulseworks, an Atlanta firm that manufactures motion simulators.

Artery Explorer is part of AstraZeneca's Us Against Athero campaign, an unbranded companion to the company's Crestor work aimed at raising awareness of the disease. Crestor is indicated for slowing the progression of the disease in patients with elevated cholesterol.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.